NovaBridge Biosciences (NBP) Debt to Equity (2018 - 2023)

NovaBridge Biosciences (NBP) has 4 years of Debt to Equity data on file, last reported at $0.02 in Q4 2023.

• Quarterly Debt to Equity rose 167.77% year-over-year to $0.02 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $0.02 (up 167.77% YoY) and the FY2023 annual result came in at $0.02, up 164.56% from the prior year.
• Debt to Equity improved to $0.02 in Q4 2023 per NBP's latest filing, from $0.01 in the prior quarter.
• Across five years, Debt to Equity topped out at $0.02 in Q4 2023 and bottomed at -$0.02 in Q4 2019.
• The 3-year median for Debt to Equity is $0.01 (2022), against an average of $0.0.
• The widest annual swing landed in 2019, when Debt to Equity surged 70.66%; it then soared 167.77% in 2023.
• Tracing NBP's Debt to Equity over 3 years: stood at -$0.02 in 2019, then surged by 126.51% to $0.01 in 2022, then soared by 167.77% to $0.02 in 2023.
• Per Business Quant, the three latest NBP Debt to Equity figures stand at $0.02 (Q4 2023), $0.01 (Q2 2023), and $0.01 (Q4 2022).

Peer Comparison